by ODWAdmin | Oct 30, 2025 | Uncategorized
Radioligand therapy (RLT) represents a paradigm shift in precision oncology, delivering targeted radiation directly to cancer cells while minimizing damage to healthy tissue. Cell line-derived xenograft (CDX) models serve as essential platforms for RLT development,...
by ODWAdmin | Oct 1, 2025 | Uncategorized
Antibody-drug conjugate (ADC) resistance represents one of the most formidable challenges in precision oncology, with clinical failures often attributed to our limited understanding of the dynamic molecular mechanisms underlying therapeutic escape. Panome Bio’s...
by ODWAdmin | Sep 30, 2025 | Uncategorized
In the fight against cancer, single-agent treatments often hit a wall as tumors adapt and develop resistance. This is especially true for aggressive cancers like non-small-cell lung cancer (NSCLC) with KRAS and LKB1 mutations, a hard-to-treat subtype. These challenges...
by ODWAdmin | Sep 29, 2025 | Uncategorized
Animal models have long been the cornerstone of biomedical research. They provide scientists with an invaluable window into disease mechanisms, treatment responses, and the intricate biology that drives health and illness. Yet, as research questions grow more complex,...
by ODWAdmin | Sep 26, 2025 | Uncategorized
Proteolysis targeting chimeras (PROTACs) represent a revolutionary approach to targeted protein degradation, offering unprecedented opportunities to modulate previously “undruggable” targets in cancer and other diseases. As PROTAC research progresses from...
by ODWAdmin | Sep 25, 2025 | Uncategorized
Antibody-drug conjugates (ADCs) represent a paradigm shift in targeted cancer therapy, combining the specificity of monoclonal antibodies with the cytotoxic potency of small molecule drugs through sophisticated linker chemistry. Despite remarkable clinical successes...
